Respicardia, Inc. Pivotal Trial of the remedē System

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT01816776

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
Respicardia, Inc. (from the registry)
Registry
  • NCT NCT01816776
Other papers using this trial's data
  • Automatic activation of neurostimulation for central sleep apnea results in high nightly usage Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026-02-27 DOI, PubMed 41761012, PMC12994950 In the PMC Open Access subset under CC BY.
  • Changes in quality of life in patients with atrial fibrillation and central sleep apnea treated with transvenous phrenic nerve stimulation Sleep medicine, 2026-05 DOI, PubMed 41643229
  • Classifying hypopneas as obstructive or central can enhance transvenous phrenic nerve stimulation therapy patient selection and outcomes Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025-12-01 DOI, PubMed 41025409, PMC12670611 In the PMC Open Access subset under CC BY.
  • Improving Nocturnal Hypoxemic Burden with Transvenous Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea Journal of cardiovascular translational research, 2021-04 DOI, PubMed 32789619, PMC8043931 PubMed links an erratum for this paper. Erratum: PMID 34761354 In the PMC Open Access subset under CC BY.
  • Transvenous phrenic nerve stimulation improves central sleep apnea, sleep quality, and quality of life regardless of prior positive airway pressure treatment Sleep & breathing = Schlaf & Atmung, 2021-12 DOI, PubMed 33745107, PMC8590675 In the PMC Open Access subset under CC BY.
  • Transvenous phrenic nerve stimulation is associated with normalization of nocturnal heart rate perturbations in patients with central sleep apnea Sleep, 2023-09-08 DOI, PubMed 37284759, PMC10485567 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01816776. Randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2016-09-10 (actual). Results posted on 2017-07-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Respicardia, Inc. Pivotal Trial of the remedē System
Condition
Sleep Apnea, Central
Condition
Sleep Disordered Breathing
Condition
Heart Failure
Intervention (Device)
Treatment Group (transvenous stimulation of the phrenic nerve)
Intervention (Device)
Control Group (Optimal Medical Therapy)
Lead sponsor
Respicardia, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01816776
Content hash
e7f7bd196e99ea8ed6923587b0239c445eec35751435e6c2a63fa54eb59d5c67